title: Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand.
abstract: We obtained specimens from 128 HIV-1 seroconverters identified from 1995 through 1998 in a prospective cohort study of 1,209 HIV-negative injecting drug users (IDUs) in Bangkok, Thailand. Epidemiologic data indicated that parenteral transmission accounted for nearly all infections. HIV-1 DNA from the C2-V4 env region was sequenced, and phylogenetic analyses determined that 102 (79.7%) of the specimens were subtype E and 26 (20.3%) subtype B strains. All subtype B strains clustered with strains often referred to in previous studies as Thai B or B'. The interstrain nucleotide distance (C2-V4) within subtype E strains was low (mean, 6.8%), and pairwise comparisons with a prototype subtype E strain, CM244, showed limited divergence (mean, 5.6%). The subtype B stains showed greater interstrain divergence (mean, 9.2%) and were significantly divergent from the prototype B strain HIV-MN (mean, 13.0%; p < 0.0001). The subtype E strains had significantly lower mean V3 loop charge than did subtype B strains (p = 0.017) and, on the basis of analysis of amino acid sequences, were predicted to be predominantly (91%) non-syncytium-inducing (NSI), chemokine coreceptor CCR5-using (CCR5+) viruses. The subtype B strains had a higher mean V3 loop charge, and a smaller proportion (23%) were predicted to be NSI/CCR5+ viruses. This study demonstrates that most incident HIV1 infections among Bangkok IDUs are due to subtype E viruses, with a narrow spectrum of genetic diversity. The characterization of incident HIV-1 strains from 1995 to 1998 will provide important baseline information for comparison with any breakthrough infections that occur among IDUs in Bangkok who are participating in an HIV-1 vaccine efficacy trial initiated in 1999.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. sfs2@cdc.gov
authors.forename: S
authors.initials: S
authors.lastname: Subbarao
authors.forename: S
authors.initials: S
authors.lastname: Vanichseni
authors.forename: D J
authors.initials: DJ
authors.lastname: Hu
authors.forename: D
authors.initials: D
authors.lastname: Kitayaporn
authors.forename: K
authors.initials: K
authors.lastname: Choopanya
authors.forename: S
authors.initials: S
authors.lastname: Raktham
authors.forename: N L
authors.initials: NL
authors.lastname: Young
authors.forename: C
authors.initials: C
authors.lastname: Wasi
authors.forename: R
authors.initials: R
authors.lastname: Sutthent
authors.forename: C C
authors.initials: CC
authors.lastname: Luo
authors.forename: A
authors.initials: A
authors.lastname: Ramos
authors.forename: T D
authors.initials: TD
authors.lastname: Mastro
mesh_terms: D000595:Amino Acid Sequence; D015331:Cohort Studies; D006031:Glycosylation; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000235:genetics; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology* / Q000821:virology*; D015497:HIV-1 / Q000145:classification* / Q000235:genetics*; D006801:Humans; D015994:Incidence; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry / Q000235:genetics; D010802:Phylogeny; D011446:Prospective Studies; D015728:Receptors, HIV / Q000378:metabolism; D017422:Sequence Analysis, DNA; D015819:Substance Abuse, Intravenous / Q000150:complications*; D013785:Thailand / Q000453:epidemiology
chemical_list: D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D015728:Receptors, HIV